AR085666A1 - Derivados de c4-monometil triterpenoides y una composicion farmaceutica - Google Patents
Derivados de c4-monometil triterpenoides y una composicion farmaceuticaInfo
- Publication number
- AR085666A1 AR085666A1 ARP120100803A ARP120100803A AR085666A1 AR 085666 A1 AR085666 A1 AR 085666A1 AR P120100803 A ARP120100803 A AR P120100803A AR P120100803 A ARP120100803 A AR P120100803A AR 085666 A1 AR085666 A1 AR 085666A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- alkylamino
- alkoxy
- groups
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003648 triterpenes Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000004423 acyloxy group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000001769 aryl amino group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- -1 hydroxy, amino Chemical group 0.000 abstract 3
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005035 acylthio group Chemical group 0.000 abstract 1
- 125000006323 alkenyl amino group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452017P | 2011-03-11 | 2011-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085666A1 true AR085666A1 (es) | 2013-10-16 |
Family
ID=45856041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100803A AR085666A1 (es) | 2011-03-11 | 2012-03-12 | Derivados de c4-monometil triterpenoides y una composicion farmaceutica |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9290536B2 (enExample) |
| EP (1) | EP2683731B1 (enExample) |
| JP (1) | JP6129084B2 (enExample) |
| KR (1) | KR101956399B1 (enExample) |
| CN (1) | CN103619866B (enExample) |
| AR (1) | AR085666A1 (enExample) |
| AU (1) | AU2012229244B2 (enExample) |
| BR (1) | BR112013023174B1 (enExample) |
| CA (1) | CA2829618C (enExample) |
| CL (1) | CL2013002612A1 (enExample) |
| CO (1) | CO6801741A2 (enExample) |
| CY (1) | CY1121744T1 (enExample) |
| DK (1) | DK2683731T3 (enExample) |
| EA (1) | EA026847B1 (enExample) |
| ES (1) | ES2729405T3 (enExample) |
| HR (1) | HRP20191164T1 (enExample) |
| HU (1) | HUE044081T2 (enExample) |
| IL (1) | IL228297B (enExample) |
| LT (1) | LT2683731T (enExample) |
| ME (1) | ME03469B (enExample) |
| MX (1) | MX348862B (enExample) |
| PL (1) | PL2683731T3 (enExample) |
| PT (1) | PT2683731T (enExample) |
| RS (1) | RS59200B1 (enExample) |
| SG (1) | SG193404A1 (enExample) |
| SI (1) | SI2683731T1 (enExample) |
| SM (1) | SMT201900433T1 (enExample) |
| TR (1) | TR201909788T4 (enExample) |
| TW (1) | TWI535731B (enExample) |
| UY (1) | UY33946A (enExample) |
| WO (1) | WO2012125488A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| HUE043175T2 (hu) | 2008-01-11 | 2019-08-28 | Reata Pharmaceuticals Inc | Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében |
| MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| CN104250280A (zh) | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| HRP20171859T1 (hr) | 2010-12-17 | 2018-01-26 | Reata Pharmaceuticals, Inc. | Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale |
| CA2829618C (en) | 2011-03-11 | 2019-07-09 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| DK3444261T3 (da) | 2012-04-27 | 2021-03-08 | Reata Pharmaceuticals Inc | 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| HRP20171565T1 (hr) * | 2012-09-10 | 2017-12-15 | Reata Pharmaceuticals, Inc. | C17-heteroaril derivati oleanolne kiseline i postupci njihove uporabe |
| MX2015003021A (es) * | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
| TW201514192A (zh) | 2013-03-19 | 2015-04-16 | Daiichi Sankyo Co Ltd | 萜類衍生物 |
| TWI649330B (zh) * | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CA2814303A1 (en) | 2013-04-26 | 2014-10-26 | Cellphone-Mate, Inc. | Apparatus and methods for radio frequency signal boosters |
| CN104861028A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型熊果酸衍生物、其制备方法及其应用 |
| CN104861027A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型齐墩果酸衍生物、其制备方法及其应用 |
| KR20170055482A (ko) | 2014-09-10 | 2017-05-19 | 다이이찌 산쿄 가부시키가이샤 | 안질환 치료용 및 예방용 서방성 의약 조성물 |
| US11059792B2 (en) | 2015-02-12 | 2021-07-13 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| EA201890767A1 (ru) | 2015-09-23 | 2019-09-30 | Рита Фармасьютикалз, Инк. | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений |
| CN105820207A (zh) * | 2016-03-24 | 2016-08-03 | 庄立 | 一种茴拉西坦的药物组合物及其抗氧化作用 |
| AU2017356955B2 (en) | 2016-11-08 | 2023-11-09 | Reata Pharmaceuticals Holdings, LLC | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| CN112654610B (zh) | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| WO2020068689A1 (en) * | 2018-09-28 | 2020-04-02 | Fronthera U.S. Pharmaceuticals Llc | Terpinoid derivatives and uses thereof |
| KR102891865B1 (ko) * | 2019-07-19 | 2025-11-26 | 리아타 파마슈티컬즈, 아이엔씨. | C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법 |
| EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| WO2022155614A1 (en) | 2021-01-18 | 2022-07-21 | Reata Pharmaceuticals, Inc. | Synthetic ursolic acid derivatives and methods of use thereof |
| MX2024008443A (es) | 2022-02-16 | 2024-07-19 | Firmenich & Cie | Proceso de preparacion de derivados de octahidro-2(1h)-naftalenona . |
| GB202211190D0 (en) * | 2022-08-01 | 2022-09-14 | Royal College Surgeons Ireland | Fluorination process |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| US6365768B1 (en) | 1999-05-14 | 2002-04-02 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
| JP2004509972A (ja) | 2000-09-29 | 2004-04-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 酵母に対する殺真菌活性を有するトリテルペン |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| EP1395255A4 (en) | 2000-11-28 | 2007-09-12 | Univ Texas | CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF |
| AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| MXPA04006953A (es) | 2002-01-18 | 2005-06-20 | Univ Minnesota | Sales cuaternarias de triperpeno como surfactantes biologicamente activos. |
| AU2003303128A1 (en) | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| CA2579231C (en) | 2004-09-07 | 2018-07-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| EP2032594B1 (en) | 2006-06-27 | 2015-09-23 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
| CN101117348B (zh) | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| HUE043175T2 (hu) | 2008-01-11 | 2019-08-28 | Reata Pharmaceuticals Inc | Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében |
| US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| CN104250280A (zh) | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| PL3254675T3 (pl) | 2009-02-13 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me |
| CN101704874A (zh) * | 2009-11-26 | 2010-05-12 | 中国药科大学 | 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途 |
| SMT202000086T1 (it) | 2010-04-12 | 2020-03-13 | Reata Pharmaceuticals Inc | Bardoxolone metile per il trattamento dell'obesità |
| WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
| JP6001560B2 (ja) | 2011-01-31 | 2016-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
| CA2829618C (en) | 2011-03-11 | 2019-07-09 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
-
2012
- 2012-03-09 CA CA2829618A patent/CA2829618C/en active Active
- 2012-03-09 HR HRP20191164TT patent/HRP20191164T1/hr unknown
- 2012-03-09 JP JP2013557919A patent/JP6129084B2/ja active Active
- 2012-03-09 EP EP12709768.1A patent/EP2683731B1/en active Active
- 2012-03-09 SG SG2013068291A patent/SG193404A1/en unknown
- 2012-03-09 ME MEP-2019-168A patent/ME03469B/me unknown
- 2012-03-09 WO PCT/US2012/028569 patent/WO2012125488A1/en not_active Ceased
- 2012-03-09 MX MX2013010429A patent/MX348862B/es active IP Right Grant
- 2012-03-09 BR BR112013023174-2A patent/BR112013023174B1/pt active IP Right Grant
- 2012-03-09 ES ES12709768T patent/ES2729405T3/es active Active
- 2012-03-09 DK DK12709768.1T patent/DK2683731T3/da active
- 2012-03-09 PL PL12709768T patent/PL2683731T3/pl unknown
- 2012-03-09 LT LTEP12709768.1T patent/LT2683731T/lt unknown
- 2012-03-09 KR KR1020137026782A patent/KR101956399B1/ko active Active
- 2012-03-09 SM SM20190433T patent/SMT201900433T1/it unknown
- 2012-03-09 RS RSP20190859 patent/RS59200B1/sr unknown
- 2012-03-09 SI SI201231611T patent/SI2683731T1/sl unknown
- 2012-03-09 UY UY0001033946A patent/UY33946A/es not_active Application Discontinuation
- 2012-03-09 TR TR2019/09788T patent/TR201909788T4/tr unknown
- 2012-03-09 AU AU2012229244A patent/AU2012229244B2/en active Active
- 2012-03-09 HU HUE12709768A patent/HUE044081T2/hu unknown
- 2012-03-09 PT PT12709768T patent/PT2683731T/pt unknown
- 2012-03-09 CN CN201280022645.4A patent/CN103619866B/zh active Active
- 2012-03-09 EA EA201391313A patent/EA026847B1/ru unknown
- 2012-03-12 TW TW101108395A patent/TWI535731B/zh active
- 2012-03-12 US US13/417,519 patent/US9290536B2/en active Active
- 2012-03-12 AR ARP120100803A patent/AR085666A1/es unknown
-
2013
- 2013-09-08 IL IL228297A patent/IL228297B/en active IP Right Grant
- 2013-09-11 CL CL2013002612A patent/CL2013002612A1/es unknown
- 2013-10-09 CO CO13240105A patent/CO6801741A2/es not_active Application Discontinuation
-
2019
- 2019-07-01 CY CY20191100690T patent/CY1121744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076171A1 (es) | Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| AR078507A1 (es) | Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion | |
| CR20140301A (es) | Derivados de betulina | |
| CL2011002990A1 (es) | Compuestos derivados de bifenilo, inhibidores de endopeptidasa neutra (nep); composición farmacéutica; combinación farmacéutica; uso del compuesto para tratar un trastorno o enfermedad tal como la hipertensión, insuficiencia cardiaca, insuficiencia renal, glaucoma, trastornos reproductivos, entre otros. | |
| AR079055A1 (es) | Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo | |
| PH12015500236A1 (en) | 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency - related conditions | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CY1121231T1 (el) | Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης | |
| CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| CO7081155A2 (es) | Inhibidores de serina/treonina cinasa | |
| TR201904340T4 (tr) | Yeni bileşikler. | |
| WO2012040641A3 (en) | Compounds for treating neurodegenerative diseases | |
| CR20140305A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| NZ711064A (en) | Pyridone-substituted pyrazolyl compounds as serine protease inhibitors | |
| PE20160862A1 (es) | Polimorfo de los inhibidores de la syk | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |